Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 2/20 | 0.42 |
| ▸ | POLG | P54098 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244162 | 0.89 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL17617662 | 0.87 | POLB (0.44) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL8400863 | 0.86 | SLC22A6 (0.47) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL14621498 | 0.85 | SLC22A6 (0.46) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL8400861 | 0.84 | HSP90AB1 (0.45) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL24790410 | 0.84 | NR3C1 (0.36) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL13715024 | 0.83 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL15531962 | 0.83 | HPRT1 (0.43) | HSP90AB1HSP90AA1 | |
| SCHEMBL1566036 | 0.83 | FGFR1 (0.63) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 | |
| SCHEMBL30759944 | 0.83 | FGFR1 (0.63) | HSP90AB1HSP90AA1POLBSLC22A6FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-01-18 | — | — | US | disclosed |
| US-9801884-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170037068-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-09 | — | — | US | disclosed |
| US-9493493-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2016-03-24 | — | — | US | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2308885-A2 | Novel compounds and methods for therapy | Gilead Sciences, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2009105513-A2 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-6767900-B2 | VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-27 | — | — | US | disclosed |
| US-20030153534-A1 | Phosphonate nucleotide compound | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| WO-2003028737-A1 | ANTI-VIRAL AGENTS AND IN-VITRO METHOD FOR THE IDENTIFICATION OF CANDIDATES ABLE TO INHIBIT BINDING OF POLYMERASE TO EPSILON | MITSUBISHI PHARMA CORPORATION (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | HSP90AB1 2370/4885HSP90AA1 2377/4885POLB 29/4885 |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | HSP90AB1 2370/4885HSP90AA1 2377/4885POLB 29/4885 |
| US-20170037068-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | HSP90AB1 2370/4885HSP90AA1 2377/4885POLB 29/4885 |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | HSP90AB1 1776/4885HSP90AA1 2588/4885POLB 501/4885 |
| US-20030153534-A1 | Phosphonate nucleotide compound | TYMP, PNP, MTAP | HSP90AB1 4330/4885HSP90AA1 4340/4885POLB 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.